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AsI 
As part of the activities to celebrate the first fifty years of the Society, the Celebration 
Committee decided to conduct a videotape interview of the two surviving founding 
members: Drs. Michael E. DeBakey and Harris B. Shumacker, Jr. Part of these two 
interviews will be shown at the 50th Annual Meeting in Chicago. The following transcript 
is from the interview with Dr. DeBakey conducted by Dr. F. Wil l iam Blaisdell, Calvin B. 
Ernst, and James S. T. Yao. 
E Wil l iam Blaisdell: We are doing this interview in 
anticipation of the 50th anniversary of The Society for 
Vascular Surgery. You are one of the two remaining found- 
ing members, and we are interested inyour appraisal of how 
the Society for Vascular Surgery came about. 
Michael E. DeBakey: To some extent, it was a result of 
the war experience. As you know, during World War I I  the 
incidence of amputations from major arterial injuries of 
both the upper and lower extremities was high. Vascular 
repair was not very successful because it was not attempted 
often enough. You may recall that Fiorendo Simeone and I 
analyzed the cases of arterial injuries during World War II, 
in which we published our experience showing a high 
incidence of failure to perform vascular surgery. This 
procedure, however, became important in these vascular 
injuries, and as a result, we set up what we called vascular 
centers. Dan Elkin was the head of one in the Green Briar 
Hotel, and Harry Shumacker was assigned to one in 
Indiana. We had to set up these centers immediately atthe 
end of the war to take care of the wounded who returned to 
the States to concentrate the personnel, because of the 
shortage of highly trained physicians, especially specialists in
neurosurgery, orthopedic surgery, and vascular surgery. 
Blaisdell: People hadn't really trained in vascular 
surgery. 
DeBakey: That's right. 
Blaisdell: So you were involved in encouraging people 
to study vascular surgery. 
DeBakey: Exactly, but we were concentrating on vas- 
cular problems in the vascular centers. This concept devel- 
oped out of the military experience and the establishment of 
these centers. A large part of the vascular surgery dealt with 
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arteriovenous fistulae. These were the patients who had 
survived the war but had an arteriovenous aneurysm that 
had to be repaired. So this was the impetus for the idea that 
vascular surgery should be a surgical specialty, which it 
wasn't at that time. Two surgeons who were interested were 
Ross Veal in Washington and George Lilly in Florida. 
George Lilly had worked with Dr. Alton Ochsner, and when 
I was a resident, George was my immediate superior as one 
of the assistants on the faculty, so I got to know him very 
well. At an American Medical Association meeting, we met 
and decided to organize such a society. They asked me i f I  
would prepare aconstitution and bylaws, which I did. Over 
the next few years we met, gradually increased the mem- 
bership, and the Society took off. 
Blaisdell: The meetings were held at the time of the 
AMA? 
DeBakey: Originally. 
Blaisdell: What was the reason for that? 
DeBakey: Largely because the surgical segment of the 
AMA was one of the major meeting places for the national 
meeting for surgeons. At that time the surgery section was 
very well led. You remember, in those days people like Fred 
Rankin, Evarts Graham, and Alton Ochsner were chairmen 
of the surgical sections of the AMA. It was only later that the 
surgical part of the AMA really lost that kind of prestige, to 
a large extent because of the American College of Surgeons. 
Blaisdell: What do you remember about those initial 
meetings? Do you remember anything about he programs? 
How they were organized? 
DeBakey: The programs were actually organized by the 
secretary, who would call upon various people to make 
presentations." Then the members began some research 
work, which they would report at the meetings. By 1950, 
there was a considerable amount of research on arterial 
prostheses, beginning with homografts. At that time, the 
interest was focused on how to preserve homografts, and we 
went to a freezing process for preservation. Arthur 
Voorhees in New York initiated a concept with the use of 
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prostheses by his experimental work on various types of 
grafts. We would make our presentations and exchange 
information atthe meetings. The discussions became lively 
because of all these fellows, I would say about 25 or 30 in the 
field. A surgeon in California, Norman Freeman, was very 
active. He had a brother in Washington who was a psychia- 
trist. I think he was one of the first to perform alobotomy. 
Norman was responsible for establishing Vascular Surgery 
at the University of California, San Francisco. I was vcry 
fond of Norman. He was full of ideas. 
Blaisdell: Now, the Homan's lecturc was established in 
that period also. 
DeBakey: That's right, the Homan's lecture, and the 
Matas medal, and later, the Leriche medal were established. 
These, too, were a stimulus for vascular surgery. Morc and 
morc interest began to develop, but from a technical 
standpoint. Something technical was needed to really take 
hold. In this respect, we had two surgical procedures, bypass 
and endarterectomy, but more important was diagnostic 
arteriography. It was the arteriogram that cnablcd us to 
identify the lesion, to actually see the arterial bed, and to 
determine that there was a good arterial bed beyond the 
block, which made the bypass applicable. 
Blaisdell: Renfi Fontaine was one of your first Homan 
Lecturers? 
DeBakey: Ren~ Fontaine was Associate Professor un- 
der Leriche in Strasbourg when I was there as a Fellow. 
When Leriche moved from Strasbourg to the College in 
Paris, which was one of the great professorships in France, 
Fontaine became head of that clinic. Fontaine really got into 
vascular surgery through sympathectomy. 
Blaisdell: That was about all you could do at that time. 
DeBakey: Yes, that is really why I went to Leriche's 
Clinic to spend a year with him, because he was the leading 
proponent of sympathectomy. 
Blaisdell: Let's go on regarding your experience with 
The Society for Vascular Surgery. You were the seventh 
President of The Society for Vascular Surgery. Were the 
early papers presented at the Society published? 
DeBakey: No, unfortunately, they were not. Only later 
were the articles presented submitted to Surgery. The 
reason for that was that Drs. Alton Ochsner and Owen 
Wangensteen, who were the editors of Surgery, had started 
this new journal. In starting a new journal, they were 
looking for scientific papers because they had to compete 
with the journals that already existed. So we immediately 
went o them and said we would submit papers to them. But 
we did not have a contract with them to publish all of our 
papers or to publish the transactions. That came later. 
Blaisdell: Do you remember what year the journal 
Surgery started? 
DeBakey: The first issue was dated January 1937. 
Blaisdell: About the time the Society started? 
DeBakey: No, the Society was formed about 10 years 
later. Not having our own journal was one of our weak- 
nesses. We talked about he possibility of starting our own 
journal. The Europeans had preceded us in developing a 
journal, but we had this informal agreement with Surgery, 
which put us in an awkward position. That was the reason 
we were a little reluctant to do anything. Moreover, Surgery 
really did a pretty good job; from 60% to 70% of the articles 
that were presented at the meetings were published. 
Blaisdell: Now, you were involved with starting the 
Journal of Vascular Surgery, but that came many, many ears 
later. 
DeBakey: Yes, much later. 
Blaisdell: Where do you think the organization is going 
in the future? Do you think we have solved all of the 
problems in vascular surgery? 
DeBakey: Not by any means. Just think for a moment, 
Bill, from your own experience. Arterial occlusive disease 
and arterial aneurysmal disease for the most part are of 
unknown origin. No matter what the cholesterol propo- 
nents ay, we still don't know the cause. And until we know 
the cause, we will not have any effective means of preven- 
tion. So the disease will continue to occur. All industrial 
countries have an increasingly older population, and we 
know that many of these diseases are also a result of time. To 
be sure, young people do not have aneurysmal and occlusive 
arterial diseases, but as you know, they will develop in most 
of them after the age of 50 years all the way up to 80 years. 
We are seeing more and more people in their late 60s, 70s, 
and 80s on whom we are operating for these diseases. We 
have an expanded market, so vascular surgeons for the 
future have an expanding role. There is no question that we 
have to continue innovative developments to advance the 
field technically. 
Blaisdell: What do you think about he interventional 
radiologists and minimal access surgery? What is their 
potential? 
DeBakey: I think that vascular surgeons hould take 
control of this for a number of reasons. First, vascular 
surgeons are the best equipped, both conceptually, and 
most important, Bill, technically. Most physicians who 
aren't in the field regard surgery as a technical exercise. But 
as you know, the conceptual spect of surgery is the driving 
force for the technical exercise. And if the technical exercise 
is really going to be effective, successful, and useful, it must 
be based upon a good concept. The vascular surgeon has 
that conceptual background to deal with this kind of 
problem. These kinds of innovations are associated with 
certain risks which can be successfully handled only by 
someone who has the conceptual capability of technically 
dealing with the risks. I therefore think that interventional 
radiology and minimal access urgery still belong in the field 
of vascular surgery and that vascular surgeons hould 
maintain control. To do this, they must be in control either 
of the radiologic equipment or the radiologist. Otherwise, 
there will be competition between radiologists and sur- 
geons, and if the radiologist controls the equipment, he will 
be able to keep the surgeon out of it. If they work together, 
however, using the equipment together, they can be suc- 
cessful. But I do think that the vascular surgeon must be 
aggressive about it. If the radiologist doesn't cooperate, 
surgeons must find a way to get their own radiologic 
equipment just as if they are going to do laparoscopic work, 
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they must get their own monitoring equipment as well as 
radiologic equipment and even scanners that they bring 
right into the operating room. In other words, the surgeon 
must be in control of what he does. If he needs aheart-lung 
machine, he brings it right into the operating room. He 
doesn't have a perfusionist telling him what he can do with 
it. Hemust be in control. 
Blaisdell: In terms of the development of the Dacron 
graft, what would be the impact of the present-day Food 
and Drug Administration when you tried to introduce the 
prosthesis? 
DeBakey: If we now tried to develop the Dacron graft 
the way we developed it, I am not sure we would have it 
today with the way they regulate things. I will give you a 
good illustration. I began to work in the laboratory actually 
making Dacron out of sheets at that time. When I went 
down to the department s ore to get some vinyon "N" 
cloth, they didn't have any. So I said, "Do you have nylon?" 
They said, "We are fresh out of nylon, but we do have a new 
material called Dacron." I felt it, and it looked good to me. 
So I bought a yard of it. You have to remember that my 
mother was a ldnd of sewing instructor. In those days when 
you were growing up as a boy, girls were supposed to sew. 
So after school, she would always have about six or seven 
young girls come to the house, and she would spend about 
an hour with them teaching them how to sew, and I sat there 
with them. She saw I was interested, so she taught me how 
to sew. In fact, I taught my wife how to sew. So I had this 
sense of what you could do with a sewing machine. I took 
this yard of Dacron cloth, I cut two sheets in the width I 
wanted, sewed the edges on each side, and made a tube out 
of it. Later, we made our own crimping, and Sterling 
Edwards deserves the credit for that. We put the graft on a 
stent, wrapped nylon thread around it, pushed it together, 
and baked it. That would change the "memory" in the fiber, 
and it would crimp. We did that all ourselves in the 
laboratory. After about two or three years of laboratory 
work, on my own, I decided that it was time to put the graft 
in a human being. We had good patency in the grafts in the 
dogs. I did not have a committee to approve it. In 1954 I 
made a bifurcation graft of the size I wanted for a human 
being and made several different sizes so I had them 
available. They weren't crimped. In 19541 put the first one 
in during an abdominal ortic aneurysm resection. That first 
patient lived, I think, for 13 years and never had any trouble. 
I kept in touch with him regularly. He died of a heart attack 
in Oklahoma. 
To show you the difference today, in 1983, I told the 
people at Bard that I  would like for them to make these 
albumin-coated grafts, because we were doing this in the 
operating room for patients on whom we would perform 
aortic resection. We would take a Dacron graft, immerse it
in albumin that is used for intravenous infusions, and then 
bake it a little bit, which would seal it. That is what I asked 
Bard to do, because they were making my Dacron grafts. 
They began making the albumin-coated grafts. The first 
year that hey made them, they sealed them in sort of a saline 
solution. But the manufacturing process was so involved 
that they said, "Let's stop for a while and see if we can do it 
some other way." To which I agreed. A year later, I think in 
1986 or 1987, we started again. We had to go to the FDA; 
they insisted on our going through the whole process from 
the beginning. We had this Dacron graft hat had been used 
successfully for over 30 years, and albumin has been used 
intravenously for over 40 years. When we put them to- 
gether, they decided we had to go through the whole 
process. We even had to do experimental work. We did it in 
dogs and had to demonstrate what had happened to the 
albumin. It was absorbed completely inabout 6 weeks, and 
you were left with the graft. It took 10 years to finally get 
approval from the FDA. In the meantime, it was approved 
all over the world. It was being used everywhere, xcept 
here. So that gives you some idea of what you would have to 
go through. There is no question that the FDA is holding 
back technical developments. Many of the pharmaceutical 
companies go abroad to do their clinical work. 
Blaisdell: What about cardiac and vascular surgery? 
Are they destined to separate completely into separate 
specialties? 
DeBakey: Well, my philosophy has long been that the 
cardiovascular system is a united system. I think it is a 
mistake to separate the heart from the rest of the vascular 
system. If you look at it from a clinical standpoint, cardio- 
vascular work is dependent on the diseases that involve the 
aorta and the four major arterial beds of the body: the 
coronary system, the branches of the aortic arch, the 
abdominal visceral vessels, and the peripheral vascular 
system of the lower extremity. When a patient comes in with 
a lesion in any one of these areas, we will study the entire 
patient. If he comes in with a lesion of the renal artery, we 
want o know what his cardiac status is. We may not perform 
coronary arteriography, which may not be necessary, but we 
will study his physical condition enough to know that he has 
a good functioning heart. If he doesn't, we may perform 
coronary arteriography. 
Blaisdell: We were on the subject of whether cardiac 
and vascular are separate specialties. There is a practical 
problem, Dr. DeBakey, of your concept, and that is that one 
trains in cardiac surgery or one trains in vascular surgery. 
And so far we haven't melded that too much. The cardiac 
surgeons certainly feel comfortable on the basis of their 
training with thoracic vascular procedures, but there is the 
issue of the peripheral vascular aspects of the surgery. 
DeBakey: Well, there is no question about hat, and my 
concept is not very popular ight now. That is evidenced by 
the fact that you have boards that separate the two. I just 
happen to think that was a mistake. There was nothing I 
could do about it at the time, except express my opinion, but 
the opinion of the majority was that they wanted aboard in 
vascular surgery, and that resulted in the separation. When 
I was head of the department, I continued to maintain my 
concept and philosophy of cardiovascular disease even 
though I established a residency program in vascular sur- 
gery in order to meet he needs of the Board. But I still think 
that from an overall standpoint, ifa cardiovascular center is 
well organized and well directed, the fact that there are 
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people who are working in the vascular and cardiac fields 
may not makc that great a diffcrence, if they are working 
together. What I am saying is, again, I am going back to the 
premise that thc conccptual consideration of surgery con- 
stitutes a very important basis for the specialty of the 
technical aspects in taking care of the patient. I f  you take 
care of the patient, you want to know all about him. If  you 
were to concentrate on just one aspect and disregard the 
other aspects, you are not going to give him the best 
possiblc are. 
Blaisdell: Lct's divert here and ask you to comment on 
the role of the Lifeline Foundation. 
DeBakey: The Lifclinc Foundation isextremely impor- 
tant because it now has a role in helping to advance and 
direct research, and it has the money to do this. That is 
extremely important for scvcral rcasons. One is that the 
National Institutes of Health (NIH), which is a major 
source of research funding, has gradually reduced support 
for clinical research. That was almost a natural development 
bccausc the basic scientists began to develop more and more 
and control thc study sections. At one time we had a surgery 
study section, and that was virtually eliminated. With the 
dccrcasc in funding in relation to the numbcr of grant 
applications, N IH  is able to fund only about 13% of the 
approved grants. Therefore, N IH  funding for research in 
thc clinical field, and cardiovascular surgery is a clinical ficld, 
has virtually dricd up. 
Blaisdelh What is your pcrception of the role of 
industry support? 
DeBakey: Industry should support rescarch, but you 
must keep in mind that industry also has its own agenda. 
The pharmaceutical industry, for example, puts quite a bit of 
money into research. The other particular industry we are 
dealing with, of course, is the device industry. Thcy ccrtaiuly 
have some obligation to support research. But the Lifeline 
Foundation creates a mcchanism by which you can put a 
little pressure on them and in a sense stimulate them to do 
so. The Lifeline Foundation was a great idea, and it is 
extremely important for the future of vascular surgery. 
Blaisdelh Where do you think The Society for Vascular 
Surgery is going to be 100 years from now? 
DeBakey: It will depend to a large extent on research in 
atherosclerosis. If, for example, we find a specific cause of 
arteriosclerosis and we find a vaccine, you will be able to 
vaccinate a child against arteriosclerosis. Then, a large part 
of vascular surgery will disappear. There will be, in my 
opinion, problems related to trauma and probably some 
diseases that we will not have completely solved by that 
time. Because the cardiovascular system is so essential to life, 
it has to be maintained, and if anything interferes with its 
proper functioning, we must find a way to correct it. 
Cardiovascular surgeons in particular, are the ones best 
capable of doing so. If  research itself does not solve the 
problem, the need for cardiovascular surgery will still be 
there. 
Blaisdell: Just a final question. What would bc your 
advice to young surgeons at this time, who might be 
thinking about entering the vascular field? 
DeBakey: I still think it is one of the most fascinating 
and challenging fields in surgery. I know neurosurgeons 
think theirs is, and other surgeons in other fields think theirs 
is. I may bc biascd, but, as you know, we have a wide variety 
of challenges in the cardiovascular field. There is so much 
from a technical, conceptual, even basic science aspect hat 
the opportunities are so much greater in the cardiovascular 
field than in other fields. Any youngster who is willing to 
commit himself to it could not find a more satisfying career. 
But he must be dedicated. He also must have a great deal of 
self discipline and be willing to give it all the time that it 
demands. If he does, he should have an extremely satisfying 
career. 
Blaisdell: Thank you very much, Dr. DeBakey. 
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